https://dermfield.com/articles/hocl-post-workout-sprays-real-antimicrobial-science-unproven-acne-prevention Derm Field en 2026-11-15T00:39:43.310Z HOCl Post-Workout Sprays: Real Antimicrobial Science, Unproven Acne Prevention https://dermfield.com/articles/mirdametinib-responses-deepen-through-year-4-in-reneu-long-term-data Derm Field en 2026-11-14T18:44:42.449Z Mirdametinib Responses Deepen Through Year 4 in ReNeu Long-Term Data https://dermfield.com/articles/roflumilast-cream-cut-infant-ad-itch-within-10-minutes-in-integument-infant Derm Field en 2026-11-14T05:34:41.781Z Roflumilast Cream Cut Infant AD Itch Within 10 Minutes in INTEGUMENT-INFANT https://dermfield.com/articles/type-2-inflammation-links-ad-prurigo-urticaria-and-bp-in-case-roundtable Derm Field en 2026-11-14T02:44:43.275Z Type 2 Inflammation Links AD, Prurigo, Urticaria and BP in Case Roundtable https://dermfield.com/articles/tebentafusp-doubles-5-year-survival-but-hla-negative-patients-still-wait Derm Field en 2026-11-14T01:34:44.085Z Tebentafusp Doubles 5-Year Survival, but HLA-Negative Patients Still Wait https://dermfield.com/articles/oral-icotrokinra-reaches-54-pasi-100-a-first-for-a-psoriasis-pill Derm Field en 2026-11-14T00:44:41.706Z Oral Icotrokinra Reaches 54% PASI 100, a First for a Psoriasis Pill https://dermfield.com/articles/cosibelimab-shows-sustained-results-in-advanced-cscc-at-2-5-years Derm Field en 2026-11-13T23:14:39.752Z Cosibelimab Shows Sustained Results in Advanced CSCC at 2.5 Years https://dermfield.com/articles/ghk-cu-boosts-collagen-at-picomolar-doses-but-nobody-has-tested-the-microbiome Derm Field en 2026-11-13T23:04:39.674Z GHK-Cu Boosts Collagen at Picomolar Doses — But Nobody Has Tested the Microbiome https://dermfield.com/articles/dermatologists-lead-gen-z-skin-care-trust-curology-survey-finds Derm Field en 2026-11-13T22:59:45.115Z Dermatologists lead Gen Z skin-care trust, Curology survey finds https://dermfield.com/articles/two-year-interpath-001-data-favor-personalized-mrna-therapy Derm Field en 2026-11-13T22:54:40.563Z Two-Year INTerpath-001 Data Favor Personalized mRNA Therapy https://dermfield.com/articles/jbs-buys-flora-for-us-542-million-entering-personal-care Derm Field en 2026-11-13T19:59:39.323Z JBS Buys Flora for US$542 Million, Entering Personal Care https://dermfield.com/articles/omalizumab-biosimilar-shows-qol-gains-in-csu-phase-3-post-hoc-data Derm Field en 2026-11-13T08:09:37.278Z Omalizumab Biosimilar Shows QoL Gains in CSU Phase 3 Post Hoc Data https://dermfield.com/articles/80-4-nf1-risk-in-toddlers-with-six-or-more-cafe-au-lait-macules Derm Field en 2026-11-13T06:44:37.368Z 80.4% NF1 Risk in Toddlers With Six or More Café-au-Lait Macules